Osteogenesis imperfecta: questions and answers

@article{Shapiro2009OsteogenesisIQ,
  title={Osteogenesis imperfecta: questions and answers},
  author={Jay R Shapiro and Paul Sponsellor},
  journal={Current Opinion in Pediatrics},
  year={2009},
  volume={21},
  pages={709–716}
}
Purpose of review Considerable attention has recently been focused on the pathogenesis, diagnosis and treatment of osteogenesis imperfecta. Two new genes have been defined in patients with recessive severe or lethal osteogenesis imperfecta types. Diagnostic concerns involve testing procedures, either skin biopsies or DNA analysis. Bisphosphonates have been accepted as ‘standard of care’ for children with osteogenesis imperfecta. However, questions remain as to the selection of patients for… Expand
Osteogenesis imperfecta: diagnosis and treatment
TLDR
Despite advances in the diagnosis and treatment of osteogenesis imperfecta, more research is needed and new antiresorptive and anabolic agents are being investigated but efficacy and safety of these drugs need to be better established before they can be used in clinical practice. Expand
An unusual presentation of osteogenesis imperfecta type I
TLDR
The authors present a case report of a 25-year-old woman who had severe low back pain associated with incapacity to walk and breast-feed post-partum and found severe osteoporosis with no abnormalities in the laboratory findings. Expand
Current and emerging treatments for the management of osteogenesis imperfecta
TLDR
Suggestions and guidelines for a therapeutic approach are indicated and updated with the most recent findings in OI diagnosis and treatment. Expand
Pharmacological and biological therapeutic strategies for osteogenesis imperfecta
TLDR
The main goals of treatment in OI are to decrease fracture incidence, relieve bone pain, and promote mobility and growth, utilizing pharmacological interventions, physical therapy, orthopedic surgery, and monitoring nutrition with appropriate calcium and vitamin D supplementation. Expand
Bisphosphonate therapy and osteogenesis imperfecta: The lived experience of children and their mothers
TLDR
Four themes emerged from the synthesis of the meaning units that reflected the experience that bisphosphonate therapy had on daily life with OI, which included living daily life in stride; normalcy is living with uncertainty; renewal with infusions; and making choices and living with the consequences. Expand
Phenotypic Variability of Osteogenesis Imperfecta Type V Caused by an IFITM5 Mutation
TLDR
In a large cohort of osteogenesis imperfecta type V (OI type V) patients (17 individuals from 12 families), the same mutation in the 5′ untranslated region (5′UTR) of the interferon‐induced transmembrane protein 5 (IFITM5) gene is identified and a detailed description of their phenotype is provided. Expand
Osteogenesis imperfecta and other defects of bone development as occasional causes of adult osteoporosis
TLDR
A consideration of the etiology of osteoporosis in young adults between the ages of puberty and age 50 years invokes two concerns: the genetic background of the individual and the role of a heritable defect in connective tissue synthesis leading to diminished bone mass. Expand
Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta.
TLDR
The benefits of cyclic infusions of ibandronate to children with OI are significant because ib andronate could significantly reduce annual bone fracture rate, increase lumbar and hip BMD, preserve vertebral morphometry of patients through inhibition of bone resorption. Expand
Osteogênese Imperfeita em cão jovem da raça pinscher
TLDR
There is a pattern of fractures and features that aid clinically and radiologically in the characterization of the disease and form the basis for case identification and diagnosis, including repetitive fractures, triangular face, bulging of the skull, bluish sclera and corneal opacity in a miniature pinscher dog. Expand
The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta
TLDR
Therapy with ibandronate in patients with OI leads to a normalisation of bone turnover markers and increasing bone density, and serum alkaline phosphatase and bone density are possible parameters to monitor bisphosphonate treatment in patientsWith OI. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
Modern approach to children with osteogenesis imperfecta
TLDR
Results allow for more efficacious corrective surgery using intramedullary rodding of the long bones and paravertegral instrumentation and justifies using bisphosphonates in order to reduce osteoclast mediated bone resorption. Expand
Treatment of Osteogenesis Imperfecta: Who, Why, What?
TLDR
These findings justify the use of bisphosphonates to reduce osteoclast-mediated bone resorption, and so tilt the remodeling balance towards an increase in bone mass. Expand
Genetic heterogeneity in osteogenesis imperfecta.
An epidemiological and genetical study of osteogenesis imperfecta (OI) in Victoria, Australia confirmed that there are at least four distinct syndromes at present called OI. The largest group ofExpand
Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta
TLDR
APD is an efficient symptomatic treatment for infants with severe osteogenesis imperfecta, but additional orthopaedic surgery is often needed, and long-term follow-up is important. Expand
Cyclic pamidronate treatment in Bruck syndrome: Proposal of a new modality of treatment
TLDR
This is the only patient with Bruck syndrome reported in the literature who was treated with pamidronate for bone fragility, and while the patient was under pamodronate treatment for initial diagnosis of osteogenesis imperfecta, diagnosis of Bruk syndrome became diagnosis of bruck syndrome. Expand
Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review
This systematic review of the effects of bisphosphonate treatment in children with osteogenesis imperfecta was conducted using the American Academy for Cerebral Palsy and Developmental MedicineExpand
Popcorn calcification in osteogenesis imperfecta: Incidence, progression, and molecular correlation
TLDR
It is demonstrated that popcorn calcifications are a frequent feature of severe OI, but do not distinguish cases with defects in collagen structure (primarily dominant type III OI) or modification (recessive type VIII OI). Expand
Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype–phenotype relationships
TLDR
The results contribute to the understanding of the etiology of OI by providing data to evaluate and refine current models relating genotype to phenotype and by providing an unbiased indication of the relative frequency of mutations in OI-associated genes. Expand
Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease.
TLDR
Histomorphometric analyses of iliac crest bone samples revealed findings similar to OI type I, with decreased cortical width and trabecular number, increased bone turnover, and preservation of the birefringent pattern of lamellar bone. Expand
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta
TLDR
Disodium pamidronate (APD) was given as monthly intravenous infusions to 28 children and adolescents with severe OI or a milder form of the disease, but with spinal compression fractures to find an effective symptomatic treatment. Expand
...
1
2
3
4
5
...